Markets:

Overview

News

Currencies

International

Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

75.98 -0.05 (-0.07%)

Streaming Delayed Price Updated: 2:51 PM EDT, Aug 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics ↗

October 07, 2022

Via Benzinga

Nektar Therapeutics's Return On Capital Employed Insights ↗

August 23, 2022

Nektar Therapeutics (NASDAQ:NKTR) brought in sales totaling $21.59 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 75.97%, resulting in a loss of $159.07...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 ↗

August 08, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 05, 2022

Via Benzinga

Expert Ratings for Nektar Therapeutics ↗

May 31, 2022

Within the last quarter, Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings:

Via Benzinga

After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring ↗

April 26, 2022

Via Benzinga

Expert Ratings for Nektar Therapeutics ↗

April 18, 2022

Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter:

Via Benzinga

Recap: Nektar Therapeutics Q2 Earnings ↗

August 04, 2022

Nektar Therapeutics (NASDAQ:NKTR) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact ↗

July 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Nektar Therapeutics's Return On Capital Employed Insights ↗

May 31, 2022

According to Benzinga Pro data, during Q1, Nektar Therapeutics (NASDAQ:NKTR) posted sales of $24.82 million. Earnings were up 37.94%, but Nektar Therapeutics still reported an overall loss of $90.39...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 05, 2022

Gainers

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

The Daily Biotech Pulse - Tuesday, April,26 ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Talk Markets

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide ↗

April 18, 2022

U.S. stocks traded higher in volatile session, with the Dow Jones gaining around 60 points toward the end of trading on Monday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 18, 2022

Gainers Natus Medical (NASDAQ:NTUS) shares rose 28.8% to $33.55 during Monday's regular session. The current volume of 3.0 million shares is 2073.2% of Natus Medical...

Via Benzinga

68 Biggest Movers From Yesterday ↗

April 19, 2022

Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core...

Via Benzinga

Mid-Day Market Update: U.S. Stocks Turn Lower; Bank of America Earnings Top Views ↗

April 18, 2022

U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

April 18, 2022

Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions....

Via Benzinga

Why Nektar Shares Are Down Almost 35% ↗

April 18, 2022

Shares of Nektar Therapeutics (NASDAQ: NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in...

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; Dow Gains 100 Points ↗

April 18, 2022

U.S. stocks traded higher this morning, with the Dow Jones adding around 100 points on Monday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022 ↗

April 18, 2022

Upgrades

Via Benzinga

Benzinga's Daily Brief On Trending Tickers For April 18, 2022: Casa Systems, Twitter, DiDi Global, And More ↗

April 18, 2022

Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 18, 2022

Gainers Natus Medical (NASDAQ:NTUS) stock rose 28.3% to $33.42 during Monday's pre-market session. The market value of their outstanding shares is at $1.1 billion....

Via Benzinga

Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program ↗

April 18, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 14, 2022

Gainers

Via Benzinga

Best Performers Since 3/14 Pivot ↗

March 22, 2022

Early last week, the US equity market pivoted, gaining 1%+ for four consecutive days between last Tuesday and last Friday. Sentiment has shifted amongst the investing community for the time being.

Via Talk Markets

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings ↗

March 20, 2022

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...

Via Benzinga

What 4 Analyst Ratings Have To Say About Nektar Therapeutics ↗

March 15, 2022

Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ:NKTR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Where Nektar Therapeutics Stands With Analysts ↗

March 15, 2022

Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.